Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) will report first quarter 2026 financial results on Wednesday, May 6, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time the same day.

Investors can find conference call details and access the live webcast via the company’s Investors events page. A replay will be archived on the website for at least 30 days.

News Market Reaction – RPRX

-0.45%

-0.45% Session close to close

In the Apr 16 session, RPRX declined 0.45%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets expectations for Royalty Pharma’s first quarter 2026 earnings release on May ...

Analysis

This announcement sets expectations for Royalty Pharma’s first quarter 2026 earnings release on May 6, 2026, with a conference call at 8:00 a.m. Eastern Time and replay access for at least 30 days. Against a backdrop of recent R&D funding deals, leadership additions, and partner trial progress, the scheduled call will provide updated financial details and portfolio metrics. Investors may focus on portfolio cash flows, new transactions, and commentary on recent regulatory and collaboration developments.

Key Figures

Earnings release date: May 6, 2026 Conference time: 8:00 a.m. Eastern Time Replay duration: at least 30 days

3 metrics

Earnings release date May 6, 2026 Scheduled first quarter 2026 financial results announcement

Conference time 8:00 a.m. Eastern Time Start time for earnings conference call and webcast

Replay duration at least 30 days Archived access to conference call and webcast

Previous Earnings date Reports

1 past event · Latest: Jan 20 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 20	Earnings date notice	Neutral	+1.6%	Announced timing of Q4 and full-year 2025 results and conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The prior earnings-date announcement was followed by a modest positive move, suggesting these scheduling releases have historically coincided with mild upside.

Recent Company History

Over recent months, Royalty Pharma reported leadership expansions, AI and regional growth hires, and multiple royalty financing deals, alongside positive Phase 3-related updates via partners. Within this backdrop, the company’s prior earnings-date announcement on Jan 20 for results on Feb 11, 2026 saw a 1.61% move. Today’s first-quarter 2026 earnings date fits into a pattern of regular, informational updates layered on top of ongoing deal and portfolio activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6637
ir@royaltypharma.com

FAQ

When will Royalty Pharma (RPRX) release its Q1 2026 results?

Royalty Pharma will release Q1 2026 results on Wednesday, May 6, 2026 before U.S. markets open. According to the company, the announcement precedes an 8:00 a.m. ET conference call and webcast for investors and analysts.

What time is Royalty Pharma's (RPRX) Q1 2026 conference call and webcast?

The conference call and webcast are scheduled for 8:00 a.m. Eastern Time on May 6, 2026. According to the company, the webcast will be simultaneous with the call and accessible via the Investors events page.

How can investors access Royalty Pharma (RPRX) Q1 2026 webcast and call details?

Investors can access webcast and call details on the company’s Investors events webpage. According to the company, the page at royaltypharma.com/investors/events will provide registration and dial-in information for the May 6, 2026 presentation.

Will Royalty Pharma (RPRX) provide a replay of the May 6, 2026 call?

Yes. According to the company, a replay of the conference call and webcast will be archived on the company website for at least 30 days following the May 6, 2026 event, allowing on-demand access for investors.

Is Royalty Pharma (RPRX) reporting Q1 2026 results before or after market open?

Royalty Pharma will report Q1 2026 results before U.S. markets open on May 6, 2026. According to the company, the early release timing is coordinated with an 8:00 a.m. ET investor webcast and call.

Where can I find the May 6, 2026 investor materials for Royalty Pharma (RPRX)?

Investor materials and webcast slides will be available on the company’s Investors events page. According to the company, presentation materials and the replay will be posted at royaltypharma.com/investors/events after the May 6, 2026 call.